Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS 41004 combination psoriasis plaque test
2010-018355-10Phase 2Completed
- Sponsor
- Almirall
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of LAS41004 IMP5, betamethasone dipropionate and tazarotene in plaque psoriasis (8 arms), sponsored by Almirall. Primary endpoint: Primary efficacy endpoint. Started Apr 2010; status: completed.
02
Drugs
LAS41004 IMP5betamethasone dipropionatetazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2010-018355-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018355-10.